Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in High-Risk, Newly Diagnosed Multiple Myeloma
NCT00075881Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2004
- Primary completion
- Oct 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Response Rate on Induction up to 24 weeks. Started Jan 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00075881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00075881.